BioSpace News Archive

IVX Health, a national provider of infusion and injection therapy for patients with multiple sclerosis, Crohn’s disease, ulcerative colitis, and other complex chronic conditions, today announced the opening of two new centers in the Chicago metropolitan area.

Nine COVID-19 patients have received PhageBank™ therapy under FDA-approved emergency allowance, with more anticipated

Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020

Post-hoc, pooled analyses of three Phase 3 trials found HRS-1 patients treated with terlipressin was associated with less RRT up to Day 90 versus placebo

Magellan Health, Inc. announced financial results for the third quarter ended September 30, 2020

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that it will report third quarter 2020 financial results after market close on Thursday, November 5, 2020

Achieve Life Sciences, Inc. announced that it will report its third quarter 2020 financial results and provide an update on the cytisinicline development program on Thursday, November 12, 2020 at 4:30PM ET.

LivaNova PLC, a market-leading medical technology and innovation company, reported results for the quarter ended September 30, 2020.

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced the commencement of COMET-1, a Phase 2b clinical trial of AR-15512 ophthalmic solution for the treatment of patients with dry eye disease.

-Product revenues of $1.54 billion, a 62% increase compared to Q3 2019- -Company raises revenue guidance; now expects 2020 product revenues of $6.0 to $6.2 billion-